Please login to the form below
Cardiovascular outcomes
This page shows the latest Cardiovascular outcomes news and features for those working in and with pharma, biotech and healthcare.
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke. ... In highlighting the lack of long-term evidence of the drug’s effect on cardiovascular outcomes, NICE also announced a
Latest news
-
Bayer’s finerenone scores FDA priority review for chronic kidney disease
Overactivation of the mineralocorticoid receptor is believed to play a key role in kidney and cardiovascular damage, through inflammatory and fibrotic processes. ... The key secondary endpoint, which measures cardiovascular outcomes, found that the
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
Also, in post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk, which included 15, 820 patients with type 2 diabetes and a median follow-up
-
Novartis scores CHMP backing for cholesterol drug Leqvio
in adults with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent and heterozygous familial hypercholesterolemia (HeFH). ... Another trial, dubbed ORION-4, is currently underway to determine if the reduction in LDL-C is coupled with an
-
Esperion gets FDA thumbs up for cholesterol drug Nexletol
outcomes study – not due to generate results until 2022 – before approval might be possible. ... Nexletol won’t be able to make a similar claim unless its cardiovascular outcomes trial comes out positive in 2022.
-
Novartis plans inclisiran trial in the UK
Swiss pharma also officially opens new London headquarters. Novartis announced yesterday that the UK will become the global centre a new clinical trial investigating inclisiran in improving cardiovascular outcomes. ... As a company working to improve and
More from news
Approximately 1 fully matching, plus 133 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... Joris Silon is Senior Vice President,
-
Treatment and prevention of cardiovascular disease
For individuals with diabetes, cardiovascular disease is the leading cause of morbidity and mortality. ... Against this backdrop, the ability to treat both type 2 diabetes by improving blood glucose control and substantially improve cardiovascular
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Prof Sir Mike Richards joins Incisive Health as senior counsel
In July 2012 he was appointed as Director for Reducing Premature Mortality on the NHS Commissioning Board (now NHS England), where he led the development of a cardiovascular outcomes strategy. ... These are vital attributes if the NHS is to navigate the
-
Teva's Mark Salyer joins Amarin
Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
World Heart Day 2020: It's time to make our clinical trials more inclusive
Disparities in cardiovascular health outcomes between different ethnic groups. Despite the progress that’s been made in treating heart disease, there is still a huge difference in mortality between white people ... Health outcomes are also related to
-
A new vision for tackling key illnesses
It also looks at other areas, such as cardiovascular and respiratory conditions, and explains how the NHS plans to change its approach in order to drive improvements in patient care and ... outcomes. Cardiovascular disease (CVD). Cardiovascular disease
-
Conference research case study
Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and ... Communication strategies and marketing messages were
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
